Grunenthal Acquires Averitas Pharma for its Peripheral Neuropathic Pain Product- Qutenza (capsaicin)
Shots:
- Grunenthal acquired Averitas Pharma in all stocks transaction- gained the commercialization rights for Qutenza
- The focus of the acquisition is to expand and strengthen its footprints in the markets of US
- Qutenza (8% capsaicin) is an analgesic and is approved by the US FDA & EU for postherpetic neuralgia (PHN) & peripheral neuropathic pain indication in adults respectively
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com